Advertisement

Antimonials and Resistance

  • Awanish Kumar
Chapter
Part of the SpringerBriefs in Immunology book series (BRIEFSIMMUN, volume 3)

Abstract

Antimonials have been known since ancient times as medicine. It is called as antimonials because antimony (Sb)—a metalloids belonging to group XV of periodic table of element present in this compound. Sb is present in trivalent Sb(III) and pentavalent Sb(V) form. In the beginning of twentieth century, Tartar Emetic, an organic trivalent form of antimony was used for treatment of sleeping sickness and Gaspar Vianna introduced the drug for the treatment of MCL in 1912. The activity of Antimonials against various clinical form of leishmaniasis was soon discovered. Since, Tartar Emetic was highly toxic for human, new less toxic and more effective Antimonials were developed and evaluated. Pentavalent [Sb(V)] salts were found to be less toxic to mammal than trivalent [Sb(III)] salts. By the end of 1940s pharmaceutical research produced the current drug in use; the closely related organic pentavalent antimonial compounds Sodium antimony Gluconate (SAG) and Meglumine antimonite.

Keywords

Antileishmanial Activity Arsenate Reductase Amastigote Form Trypanothione Reductase Flagellar Pocket 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Berman JD, Gallalee JV (1987) In vitro antileishmanial activity of inhibitors of steroid biosynthesis and combinations of antileishmanial agents. J Parasitol 73:671–673PubMedCrossRefGoogle Scholar
  2. Brochu C, Wang J, Roy G, Messier N, Wang XY, Saravia NG, Ouellette M (2003) Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother 47:3073–3079PubMedCrossRefGoogle Scholar
  3. Croft AM, Taylor NA, Rodenhurst KE (2006) Sandflies & leishmaniasis. Lancet 367:112PubMedCrossRefGoogle Scholar
  4. Cunningham ML, Fairlamb AH (1995) Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials. Eur J Biochem 230:460–468PubMedCrossRefGoogle Scholar
  5. Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D (1999) Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 43:278–282PubMedGoogle Scholar
  6. Goyard S, Segawa H, Gordon J, Showalter M, Duncan R, Turco SJ, Beverley SM (2003) An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol Biochem Parasitol 130:31–42PubMedCrossRefGoogle Scholar
  7. Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M (1997) Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J 16:3057–3065PubMedCrossRefGoogle Scholar
  8. Haimeur A, Guimond C, Pilote S, Mukhopadhyay R, Rosen BP, Poulin R, Ouellette M (1999) Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol 34:726–735PubMedCrossRefGoogle Scholar
  9. Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, Ouellette M, Rosen BP (1996) Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci USA 93:10383–10387PubMedCrossRefGoogle Scholar
  10. Ouellette M, Borst P (1991) Drug resistance and P-glycoprotein gene amplification in the protozoan parasite Leishmania. Res Microbiol 142:737–746PubMedCrossRefGoogle Scholar
  11. Perez-Victoria JM, Di Pietro A, Barron D, Ravelo AG, Castanys S, Gamarro F (2002) Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr Drug Targets 3:311–333PubMedCrossRefGoogle Scholar
  12. Sereno D, Holzmuller P, Mangot I, Cuny G, Ouaissi A, Lemesre JL (2001) Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob Agents Chemother 45:2064–2069PubMedCrossRefGoogle Scholar
  13. Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D (2001) Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem 276:3971–3976PubMedCrossRefGoogle Scholar
  14. Sundar S (2001a) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6:849–854PubMedCrossRefGoogle Scholar
  15. Sundar S (2001b) Liposomal amphotericin B. Lancet 357:801–802PubMedCrossRefGoogle Scholar
  16. Vickers TJ, Wyllie S, Fairlamb AH (2004) Leishmania major elongation factor 1B complex has trypanothione S-transferase and peroxidase activity. J Biol Chem 279:49003–49009PubMedCrossRefGoogle Scholar
  17. Wyllie S, Cunningham ML, Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279:39925–39932PubMedCrossRefGoogle Scholar
  18. Yan S, Li F, Ding K, Sun H (2003) Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione. J Biol Inorg Chem 8:689–697PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Awanish Kumar
    • 1
  1. 1.School of Life SciencesJawaharlal UniversityNew DelhiIndia

Personalised recommendations